| | | | | | 
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies
and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against
nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective
Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein
XPO1. The company was founded in 2008 with a vision of pioneering a potentially new approach to treating
patients with certain blood cancers. US-NON-08/18-00002 (1/2021) For more information visit our Company Website and Product Website | Back to Exhibit Hall | | | |
| | | | Meet with Gregg 
Gregg Stewart
Hematology/Oncology Specialist - Pittsburgh, PA
724-316-4448 | Gregg.Stewart@karyopharm.com Information to join Zoom: Meeting URL
Meeting ID: 926 4481 3946
Passcode: 085776 Phone: US: +13126266799,,92644813946#,,,,*085776# or
| | 
Learn more about XPOVIO Indications Learn more about our MOA Prescribing Information Patient Resources Social Media Links: Twitter LinkedIn You Tube Facebook | | | |
